Updated NETs Clinical Trials

Studies found on ClinicalTrials.gov by a search of: neuroendocrine NOT Melanoma NOT PMS | Recruiting, Not yet recruiting, Available Studies | Phase 2, 3, 4 | Last update posted in the last 30 days
  1. Conditions:   VHL Pancreatic Neuroendocrine Tumors;   Von Hippel-Lindau Disease;   Neuroendocrine Tumors
    Intervention:   Drug: 68-Gallium DOTATATE
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  2. Conditions:   Neuroendocrine Tumors;   Liver Metastases
    Intervention:   Drug: Lutetium Lu 177-DOTATATE
    Sponsor:   Marnix Lam
    Recruiting
  3. Condition:   Neuroendocrine Tumors
    Intervention:   Drug: 64Cu-SARTATE
    Sponsor:   Clarity Pharmaceuticals Ltd
    Not yet recruiting
  4. Condition:   High Grade Neuroendocrine Neoplasms
    Interventions:   Drug: Cabozantinib;   Procedure: Blood for plasma biomarkers
    Sponsors:   Washington University School of Medicine;   Exelixis
    Not yet recruiting
  5. Conditions:   Neuroendocrine Tumors;   Neuroendocrine Carcinoma;   Temozolomide;   Capecitabine
    Intervention:   Drug: TEMCAP
    Sponsor:   Asan Medical Center
    Recruiting
  6. Condition:   High Grade Malignant Neuroendocrine Carcinoma (Diagnosis)
    Interventions:   Drug: Pembrolizumab;   Drug: Irinotecan;   Drug: Paclitaxel
    Sponsors:   University of California, San Francisco;   Merck Sharp & Dohme Corp.
    Recruiting
  7. Conditions:   Metastatic Large Cell Neuroendocrine Carcinoma;   Metastatic Neuroendocrine Carcinoma;   Metastatic Neuroendocrine Neoplasm;   Metastatic Small Cell Carcinoma
    Interventions:   Drug: Cabozantinib;   Drug: Cabozantinib S-malate;   Biological: Ipilimumab;   Biological: Nivolumab
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  8. Condition:   Gastrointestinal Tumors, Urinary System Tumors, Neuroendocrine Tumors
    Interventions:   Drug: AK105;   Drug: Anlotinib
    Sponsor:   Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
    Recruiting
  9. Conditions:   Atypical Carcinoid Tumor;   Carcinoid Tumor;   Digestive System Neuroendocrine Neoplasm;   Functioning Pancreatic Neuroendocrine Tumor;   Intermediate Grade Lung Neuroendocrine Neoplasm;   Low Grade Lung Neuroendocrine Neoplasm;   Lung Atypical Carcinoid Tumor;   Lung Carcinoid Tumor;   Metastatic Digestive System Neuroendocrine Tumor G1;   Neuroendocrine Neoplasm;   Non-Functioning Pancreatic Neuroendocrine Tumor;   Pancreatic Neuroendocrine Tumor;   Serotonin-Producing Pancreatic Neuroendocrine Tumor;   Stage IIIA Digestive System Neuroendocrine Tumor AJCC v7;   Stage IIIB Digestive System Neuroendocrine Tumor AJCC v7;   Stage IV Digestive System Neuroendocrine Tumor AJCC v7
    Interventions:   Drug: Cabozantinib S-malate;   Other: Laboratory Biomarker Analysis;   Other: Placebo Administration;   Other: Quality-of-Life Assessment
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  10. Conditions:   Metastatic Well Differentiated Neuroendocrine Neoplasm;   Neuroendocrine Tumors
    Interventions:   Drug: Cabozantinib;   Drug: Lanreotide
    Sponsor:   Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
    Not yet recruiting
  11. Condition:   Neuroendocrine Tumors
    Interventions:   Drug: 177Lu-edotreotide PRRT;   Drug: Everolimus;   Other: Amino-Acid Solution
    Sponsors:   ITM Solucin GmbH;   ABX CRO
    Recruiting
  12. Condition:   Carcinoma, Neuroendocrine
    Intervention:   Drug: [177]Lu-DOTA-TATE
    Sponsor:   AHS Cancer Control Alberta
    Recruiting
  13. Conditions:   Gastroenteropancreatico Tumors;   Neuroendocrine Tumors;   Neuroendocrine Neoplasms
    Interventions:   Drug: Lu-177-DOTATATE;   Drug: Olaparib;   Diagnostic Test: Ga dotatate scanning;   Diagnostic Test: FDG-PET scanning
    Sponsor:   National Cancer Institute (NCI)
    Not yet recruiting
  14. Condition:   Gastro-enteropancreatic Neuroendocrine Tumor
    Interventions:   Drug: Lutathera;   Drug: long-acting octreotide;   Drug: high dose long-acting octreotide
    Sponsor:   Advanced Accelerator Applications
    Recruiting
  15. Conditions:   Acinar Cell Carcinoma;   Adenoid Cystic Carcinoma;   Adrenal Cortex Carcinoma;   Adrenal Gland Pheochromocytoma;   Anal Canal Neuroendocrine Carcinoma;   Anal Canal Undifferentiated Carcinoma;   Angiosarcoma;   Apocrine Neoplasm;   Appendix Mucinous Adenocarcinoma;   Bartholin Gland Transitional Cell Carcinoma;   Basal Cell Carcinoma;   Bladder Adenocarcinoma;   Cervical Adenocarcinoma;   Cervical Clear Cell Adenocarcinoma;   Cholangiocarcinoma;   Chordoma;   Colorectal Squamous Cell Carcinoma;   Desmoid-Type Fibromatosis;   Endometrial Transitional Cell Carcinoma;   Endometrioid Adenocarcinoma;   Esophageal Neuroendocrine Carcinoma;   Esophageal Undifferentiated Carcinoma;   Extrahepatic Bile Duct Carcinoma;   Extramammary Paget Disease;   Fallopian Tube Adenocarcinoma;   Fallopian Tube Transitional Cell Carcinoma;   Fibromyxoid Tumor;   Gallbladder Carcinoma;   Gastric Neuroendocrine Carcinoma;   Gastric Squamous Cell Carcinoma;   Gastric Undifferentiated Carcinoma;   Gastrointestinal Stromal Tumor;   Gestational Trophoblastic Tumor;   Giant Cell Carcinoma;   Intestinal Neuroendocrine Carcinoma;   Intrahepatic Cholangiocarcinoma;   Lung Carcinoid Tumor;   Lung Sarcomatoid Carcinoma;   Major Salivary Gland Carcinoma;   Malignant Odontogenic Neoplasm;   Malignant Peripheral Nerve Sheath Tumor;   Malignant Testicular Sex Cord-Stromal Tumor;   Metaplastic Breast Carcinoma;   Metastatic Malignant Neoplasm of Unknown Primary;   Minimally Invasive Lung Adenocarcinoma;   Mixed Mesodermal (Mullerian) Tumor;   Mucinous Adenocarcinoma;   Mucinous Cystadenocarcinoma;   Nasal Cavity Adenocarcinoma;   Nasal Cavity Carcinoma;   Nasopharyngeal Carcinoma;   Nasopharyngeal Papillary Adenocarcinoma;   Nasopharyngeal Undifferentiated Carcinoma;   Oral Cavity Carcinoma;   Oropharyngeal Undifferentiated Carcinoma;   Ovarian Adenocarcinoma;   Ovarian Clear Cell Adenocarcinoma;   Ovarian Germ Cell Tumor;   Ovarian Mucinous Adenocarcinoma;   Ovarian Squamous Cell Carcinoma;   Ovarian Transitional Cell Carcinoma;   Pancreatic Acinar Cell Carcinoma;   Pancreatic Neuroendocrine Carcinoma;   Paraganglioma;   Paranasal Sinus Adenocarcinoma;   Paranasal Sinus Carcinoma;   Parathyroid Gland Carcinoma;   PEComa;   Peritoneal Mesothelioma;   Pituitary Gland Carcinoma;   Placental Choriocarcinoma;   Primary Peritoneal High Grade Serous Adenocarcinoma;   Pseudomyxoma Peritonei;   Rare Disorder;   Scrotal Squamous Cell Carcinoma;   Seminal Vesicle Adenocarcinoma;   Seminoma;   Serous Cystadenocarcinoma;   Small Intestinal Adenocarcinoma;   Small Intestinal Squamous Cell Carcinoma;   Solid Neoplasm;   Spindle Cell Neoplasm;   Squamous Cell Carcinoma of the Penis;   Teratoma With Somatic-Type Malignancy;   Testicular Non-Seminomatous Germ Cell Tumor;   Thyroid Gland Carcinoma;   Tracheal Carcinoma;   Transitional Cell Carcinoma;   Ureter Adenocarcinoma;   Ureter Squamous Cell Carcinoma;   Urethral Adenocarcinoma;   Urethral Squamous Cell Carcinoma;   Vaginal Adenocarcinoma;   Vaginal Squamous Cell Carcinoma, Not Otherwise Specified;   Vulvar Carcinoma
    Interventions:   Procedure: Biospecimen Collection;   Biological: Ipilimumab;   Biological: Nivolumab
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  16. Conditions:   KRAS Gene Mutation;   Metastatic Colorectal Carcinoma;   NRAS Gene Mutation;   Stage III Colorectal Cancer AJCC v8;   Stage IIIA Colorectal Neuroendocrine Tumor AJCC v8;   Stage IIIB Colorectal Cancer AJCC v8;   Stage IIIC Colorectal Cancer AJCC v8;   Stage IV Colorectal Cancer AJCC v8;   Stage IVA Colorectal Cancer AJCC v8;   Stage IVB Colorectal Cancer AJCC v8;   Stage IVC Colorectal Cancer AJCC v8;   Unresectable Carcinoma
    Interventions:   Drug: Binimetinib;   Drug: Palbociclib;   Drug: Trifluridine and Tipiracil Hydrochloride
    Sponsors:   Academic and Community Cancer Research United;   National Cancer Institute (NCI)
    Recruiting
  17. Conditions:   Bladder Adenocarcinoma;   Bladder Mixed Adenocarcinoma;   Bladder Small Cell Carcinoma;   Bladder Squamous Cell Carcinoma;   Chromophobe Renal Cell Carcinoma;   Infiltrating Bladder Lymphoepithelioma-Like Carcinoma;   Infiltrating Bladder Urothelial Carcinoma;   Infiltrating Bladder Urothelial Carcinoma With Giant Cells;   Infiltrating Bladder Urothelial Carcinoma, Nested Variant;   Infiltrating Bladder Urothelial Carcinoma, Plasmacytoid Variant;   Infiltrating Bladder Urothelial Carcinoma, Sarcomatoid Variant;   Kidney Medullary Carcinoma;   Large Cell Neuroendocrine Carcinoma;   Metastatic Bladder Carcinoma;   Metastatic Bladder Large Cell Neuroendocrine Carcinoma;   Metastatic Bladder Small Cell Carcinoma;   Metastatic Bladder Squamous Cell Carcinoma;   Metastatic Infiltrating Bladder Urothelial Carcinoma, Clear Cell Variant;   Metastatic Infiltrating Bladder Urothelial Carcinoma, Lipid-Rich Variant;   Metastatic Infiltrating Bladder Urothelial Carcinoma, Micropapillary Variant;   Metastatic Infiltrating Bladder Urothelial Carcinoma, Plasmacytoid Variant;   Metastatic Infiltrating Bladder Urothelial Carcinoma, Sarcomatoid Variant;   Metastatic Kidney Medullary Carcinoma;   Metastatic Malignant Genitourinary System Neoplasm;   Metastatic Penile Carcinoma;   Metastatic Prostate Small Cell Carcinoma;   Metastatic Sarcomatoid Renal Cell Carcinoma;   Papillary Renal Cell Carcinoma;   Sarcomatoid Renal Cell Carcinoma;   Stage IV Bladder Cancer AJCC v8;   Stage IV Penile Cancer AJCC v8;   Stage IV Prostate Cancer AJCC v8;   Stage IV Renal Cell Cancer AJCC v8;   Stage IVA Bladder Cancer AJCC v8;   Stage IVA Prostate Cancer AJCC v8;   Stage IVB Bladder Cancer AJCC v8;   Stage IVB Prostate Cancer AJCC v8;   Testicular Leydig Cell Tumor;   Testicular Sertoli Cell Tumor
    Interventions:   Drug: Cabozantinib;   Drug: Cabozantinib S-malate;   Biological: Ipilimumab;   Biological: Nivolumab
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  18. Conditions:   Appendix Adenocarcinoma;   Human Papillomavirus-Related Anal Squamous Cell Carcinoma;   Human Papillomavirus-Related Cervical Squamous Cell Carcinoma;   Human Papillomavirus-Related Squamous Cell Carcinoma of the Penis;   Human Papillomavirus-Related Vulvar Squamous Cell Carcinoma;   Neuroendocrine Carcinoma;   Pancreatic Neuroendocrine Tumor;   Recurrent Merkel Cell Carcinoma;   Recurrent Nasopharynx Carcinoma;   Recurrent Peritoneal Malignant Mesothelioma;   Recurrent Pleural Malignant Mesothelioma;   Stage III Merkel Cell Carcinoma AJCC v7;   Stage III Nasopharyngeal Carcinoma AJCC v7;   Stage III Pleural Malignant Mesothelioma AJCC v7;   Stage IV Merkel Cell Carcinoma AJCC v7;   Stage IV Nasopharyngeal Carcinoma AJCC v7;   Stage IV Pleural Malignant Mesothelioma AJCC v7;   Stage IVA Nasopharyngeal Carcinoma AJCC v7;   Stage IVB Nasopharyngeal Carcinoma AJCC v7;   Stage IVC Nasopharyngeal Carcinoma AJCC v7;   Vaginal Squamous Cell Carcinoma, Not Otherwise Specified
    Interventions:   Drug: Atezolizumab;   Biological: Bevacizumab;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting
  19. Condition:   Medullary Thyroid Cancer
    Interventions:   Drug: Selpercatinib;   Drug: Cabozantinib;   Drug: Vandetanib
    Sponsors:   Eli Lilly and Company;   Loxo Oncology, Inc. a wholly owned subsidiary of Eli Lilly and Company
    Recruiting
  20. Conditions:   Carcinoma, Non-Small -Cell Lung;   Ovarian Neoplasms;   Small Cell Lung Carcinoma;   Uterine Cervical Neoplasms;   Carcinoma, Neuroendocrine;   Extrapulmonary Small Cell Cancer
    Interventions:   Drug: Topotecan;   Drug: VX-970 (M6620)
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  21. Conditions:   Solid Tumor;   Medullary Thyroid Cancer
    Intervention:   Drug: Selpercatinib
    Sponsors:   Eli Lilly and Company;   Loxo Oncology, Inc. a wholly owned subsidiary of Eli Lilly and Company
    Recruiting
  22. Conditions:   Advanced Solid Tumors;   Glioblastoma;   Soft Tissue Sarcoma;   Endometrial Carcinoma;   Ovarian Carcinoma;   Mesothelioma;   Gastroenteropancreatic Neuroendocrine Tumor;   SCLC;   Gastric Carcinoma
    Interventions:   Drug: lurbinectedin (PM01183);   Drug: Irinotecan
    Sponsor:   PharmaMar
    Recruiting
  23. Conditions:   Locally Advanced Solid Tumors;   Metastatic Solid Tumors
    Intervention:   Drug: Oral repotrectinib (TPX-0005)
    Sponsor:   Turning Point Therapeutics, Inc.
    Recruiting
  24. Conditions:   Adrenal Cortex Carcinoma;   Alveolar Soft Part Sarcoma;   Central Nervous System Neoplasm;   Childhood Clear Cell Sarcoma of Soft Parts;   Clear Cell Sarcoma of Soft Tissue;   Ewing Sarcoma;   Hepatoblastoma;   Hepatocellular Carcinoma;   Osteosarcoma;   Recurrent Adrenal Cortex Carcinoma;   Recurrent Alveolar Soft Part Sarcoma;   Recurrent Ewing Sarcoma;   Recurrent Hepatoblastoma;   Recurrent Hepatocellular Carcinoma;   Recurrent Malignant Solid Neoplasm;   Recurrent Osteosarcoma;   Recurrent Primary Malignant Central Nervous System Neoplasm;   Recurrent Renal Cell Carcinoma;   Recurrent Rhabdomyosarcoma;   Recurrent Soft Tissue Sarcoma;   Recurrent Thyroid Gland Medullary Carcinoma;   Refractory Ewing Sarcoma;   Refractory Malignant Solid Neoplasm;   Refractory Osteosarcoma;   Refractory Primary Malignant Central Nervous System Neoplasm;   Refractory Rhabdomyosarcoma;   Refractory Soft Tissue Sarcoma;   Renal Cell Carcinoma;   Rhabdomyosarcoma;   Solid Neoplasm;   Thyroid Gland Medullary Carcinoma;   Wilms Tumor
    Interventions:   Drug: Cabozantinib;   Drug: Cabozantinib S-malate;   Other: Pharmacological Study
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  25. Conditions:   Non-Small Cell Lung Cancer;   Medullary Thyroid Cancer;   Colon Cancer;   Any Solid Tumor
    Intervention:   Drug: LOXO-292 (selpercatinib)
    Sponsors:   Loxo Oncology, Inc.;   Eli Lilly and Company
    Recruiting
  26. Condition:   Breast Cancer
    Interventions:   Drug: alpelisib;   Drug: fulvestrant;   Drug: letrozole;   Drug: Goserelin;   Drug: Leuprolide
    Sponsor:   Novartis Pharmaceuticals
    Recruiting
  27. Condition:   Cushing's Syndrome
    Intervention:   Drug: osilodrostat
    Sponsor:   Novartis Pharmaceuticals
    Recruiting
  28. Conditions:   Metastatic Renal Cell Carcinoma;   Advanced Retinal Disease Carcinoma;   Renal Medullary Carcinoma
    Interventions:   Drug: Talazoparib;   Drug: Avelumab
    Sponsor:   Memorial Sloan Kettering Cancer Center
    Recruiting
  29. Conditions:   Pathologic Stage I Merkel Cell Carcinoma AJCC v8;   Pathologic Stage II Merkel Cell Carcinoma AJCC v8;   Pathologic Stage IIA Merkel Cell Carcinoma AJCC v8;   Pathologic Stage IIB Merkel Cell Carcinoma AJCC v8;   Pathologic Stage III Merkel Cell Carcinoma AJCC v8;   Pathologic Stage IIIA Merkel Cell Carcinoma AJCC v8;   Pathologic Stage IIIB Merkel Cell Carcinoma AJCC v8
    Interventions:   Other: Best Practice;   Biological: Pembrolizumab;   Radiation: Radiation Therapy
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  30. Condition:   Metastatic Merkel Cell Carcinoma
    Intervention:   Drug: Retifanlimab
    Sponsor:   Incyte Corporation
    Recruiting
  31. Conditions:   Stage III Merkel Cell Carcinoma AJCC v8;   Stage IIIB Merkel Cell Carcinoma AJCC v8;   Stage IIIA Merkel Cell Carcinoma AJCC v8
    Interventions:   Drug: Avelumab;   Other: Peripheral Blood Collection;   Other: Placebo
    Sponsors:   University of Washington;   National Cancer Institute (NCI);   EMD Serono
    Recruiting
  32. Conditions:   Adenoid Cystic Carcinoma;   Adnexal Carcinoma;   Apocrine Carcinoma;   Extraocular Cutaneous Sebaceous Carcinoma;   Hidradenocarcinoma;   Keratoacanthoma;   Malignant Sweat Gland Neoplasm;   Merkel Cell Carcinoma;   Microcystic Adnexal Carcinoma;   NK-Cell Lymphoma, Unclassifiable;   Paget Disease;   Papillary Adenocarcinoma;   Porocarcinoma;   Primary Cutaneous Mucinous Carcinoma;   Recurrent Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma;   Recurrent T-Cell Non-Hodgkin Lymphoma;   Refractory Anaplastic Large Cell Lymphoma;   Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma;   Refractory Merkel Cell Carcinoma;   Refractory Mycosis Fungoides;   Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma;   Refractory Skin Squamous Cell Carcinoma;   Refractory T-Cell Non-Hodgkin Lymphoma;   Sezary Syndrome;   Signet Ring Cell Carcinoma;   Skin Basal Cell Carcinoma;   Skin Basosquamous Cell Carcinoma;   Skin Squamous Cell Carcinoma;   Spiradenocarcinoma;   Squamous Cell Carcinoma of Unknown Primary;   Stage III Skin Cancer;   Stage IV Skin Cancer;   Sweat Gland Carcinoma;   Trichilemmal Carcinoma;   Vulvar Squamous Cell Carcinoma
    Interventions:   Other: Laboratory Biomarker Analysis;   Biological: Nivolumab;   Biological: Talimogene Laherparepvec
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  33. Conditions:   Cancer;   Neoplasms;   Metastatic Cancer;   Triple Negative Breast Cancer;   Gastric Cancer;   Cervical Cancer;   Ovarian Cancer;   Hepatocellular Carcinoma;   Squamous Cell Carcinoma of Head and Neck;   Urothelial Carcinoma;   Urothelial Neoplasm;   Non Small Cell Lung Cancer;   Renal Cell Carcinoma;   Locally Advanced Solid Tumor;   Locally Advanced Malignant Neoplasm;   Squamous Cell Carcinoma;   Sarcoma;   Merkel Cell Carcinoma;   Bladder Cancer
    Interventions:   Drug: OC-001;   Drug: OC-001 in Combination
    Sponsor:   Ocellaris Pharma, Inc.
    Not yet recruiting
  34. Conditions:   Neurofibromatosis 2;   Vestibular Schwannoma;   Meningioma;   Ependymoma;   Glioma
    Intervention:   Drug: Selumetinib
    Sponsors:   Children's Hospital Medical Center, Cincinnati;   AstraZeneca
    Recruiting
  35. Conditions:   Adrenocortical Carcinoma;   Pheochromocytoma;   Paraganglioma
    Intervention:   Biological: EO2401
    Sponsor:   Enterome
    Not yet recruiting